Brochure | June 13, 2019

Ibex™ Design

Source: Lonza Pharma & Biotech

The demand for biopharmaceutical products is continuously growing to serve the needs of an aging global population and the prevalence of chronic diseases. At the same time, the environment for biopharma companies is complex and challenging, with novel regulatory pathways, requirements to accelerate patient access, and rising competition.

Speed with confidence in delivery

To help you navigate through uncertainty, de-risk and accelerate your clinical development, we have created Ibex™ Design, an innovative CDMO service offering for antibodies and antibodylike molecules.

Ibex™ Design includes a pioneering gene-to-vial package, delivering drug product for your clinical trials, within 12 months. Also included are submission-ready CMC data for your IND/IMPD and a manufacturing slot reserved for your clinical resupply needs.

To take you to IND-ready in 12 months, Ibex™ Design relies on:

  • A proven platform process powered by our GS Gene Expression System®
  • A highly automated facility that drives timeline reductions and efficiency gains
  • Single-use technology that reduces manufacturing time
  • PAT2 and novel drying technologies that reduce lyophilization time
  • Integrated drug substance and drug product development capabilities that support a holistic development strategy with the endpoint in mind